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The doses of donor-derived natural killer (NK) cells that can be given safely after human leukocyte antigen
(HLA)-haploidentical hematopoietic cell transplantation (HCT) remain to be deﬁned. Forty-one patients (ages
17 to 75 years) with hematologic malignancy underwent HLA-haploidentical HCT after reduced-intensity
conditioning containing busulfan, ﬂudarabine, and antithymocyte globulin. Cell donors (ages 7 to 62 years)
underwent growth factor-mobilized leukapheresis for 3 to 4 days. Cells collected on the ﬁrst 2 to 3 days were
used for HCT, whereas those collected on the last day were CD3-depleted and cultured into NK cells using
human interleukins-15 and -21. These NK cells were then infused into patients twice at 2 and 3 weeks after
HCT at an escalating doses of .2  108 cells/kg of body weight (3 patients), .5  108 cells/kg (3 patients),
1.0  108 cells/kg (8 patients), and  1.0  108 cells/kg or available cells (27 patients). At all dose levels, no
acute toxicity was observed after NK cell infusion. After HLA-haploidentical HCT and subsequent donor NK
cell infusion, when referenced to 31 historical patients who had undergone HLA-haploidentical HCT after the
same conditioning regimen but without high-dose NK cell infusion, there was no signiﬁcant difference in the
cumulative incidences of major HCT outcomes, including engraftment (absolute neutrophil count  500/mL,
85% versus 87%), grade 2 to 4 acute graft-versus-host disease (GVHD, 17% versus 16%), moderate to severe
chronic GVHD (15% versus 10%), and transplantation-related mortality (27% versus 19%). There was, however,
a signiﬁcant reduction in leukemia progression (74% to 46%), with post-transplantation NK cell infusion being
an independent predictor for less leukemia progression (hazard ratio, .527). Our ﬁndings showed that, when
given 2 to 3 weeks after HLA-haploidentical HCT, donor-derived NK cells were well tolerated at a median total
dose of 2.0  108 cells/kg. In addition, they may decrease post-transplantation progression of acute leukemia.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic cell transplantation (HCT) from
a family member donor with a fully mismatched human
leukocyte antigen (HLA)-haplotype is being performed in-
creasingly using reduced-intensity conditioning [1-6]. These
reduced-intensity conditioning regimens feature the use of
monoclonal [2] or polyclonal antibodies [1,4] against T cells;ual Meeting of the American Society of
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14.01.031alternatively, the conditioning is followed by early post-
transplantation administration of cyclophosphamide [3,5,6].
Such transplantation approaches produced consistent donor
cell engraftment (>90%) with low incidences of grade 2 to 4
acute graft-versus-host disease (GVHD; <35%), chronic GVHD
(<35%), and transplantation-related mortality (TRM; <32%).
However, recurrence of underlyingmalignantdiseaseafterHCT
remains themost frequent causeof treatment failure, especially
in patients with active disease at the time of HCT [4,5].
Natural killer (NK) cells, a unique subset of lymphocytes,
express CD56, but not CD3 [7,8]. Unlike T cells, they can kill
tumor cells without prior sensitization of their host. NK cell
activation is enhanced by the decreased expression of major
histocompatibility complex (MHC) class I antigen on tumor
cells because of a failure to engage inhibitory receptors,
notably killer immunoglobulin-like receptors (KIR) on NKTransplantation.
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murine models, donor-type NK cells exhibited antileukemia
effector function without GVHD when given after allogeneic
HCT. It was postulated that the normal host tissues lack
activating ligands and, thus, avoid donor NK cellemediated
tissue damage [14,15].
Adoptive transfer of NK cells from an HLA-haploidentical
donor to patients with malignancies has been performed
after HLA-haploidentical HCT [16-19], during autologous HCT
[20], and without prior HCT [21-24]. In most studies, donor
NK cells were obtained from lymphapheresis products using
a magnetic-activated cell sorting system [16-18,20-22], to
generate approximately 1 to 3  107 NK cells/kg of patient
body weight from a single-day lymphapheresis product
[20-22]. Alternatively, donor NK cells were generated from
CD34þ progenitor cells from mobilized leukapheresis prod-
ucts [19,25], with yields of up to 2.5  107 cells/kg after a
6-week culture [19].
When we generated NK cells from the CD3þ cellede-
pleted portion (as opposed to CD34þ cells) of the mobilized
leukapheresis product, more cells were obtained in a shorter
time period. Therefore, we were able to examine the clinical
effect of a high dose of donor-derived NK cells given soon
after HLA-haploidentical HCT.
METHODS
Patients, HLA-Haploidentical HCT, and Donor NK Cell Infusion
This protocol for HLA-haploidentical HCT with subsequent donor NK cell
infusion (DNKI) (Figure 1A) was initiated in February 2009, and 43 consec-
utive, eligible patients had enrolled by May 2012. Of those, 2 patients died
during conditioning therapy and were excluded. The remaining 41 patients
received at least 1 DNKI after HCT and were assessed. Twelve patients in the
study were unable to ﬁnd a suitable HLA-matched donor in their family or
donor registries. The rest of the patients underwent haploidentical HCT as a
salvage treatment regardless of matched donor availability. All enrolled pa-
tients met the inclusion criteria of a diagnosis of hematologic malignancy or
myelodysplastic syndrome (MDS), a Karnofsky performance scale index 70,
and adequate organ function (total bilirubin <3.0 mg/dL, aspartate amino-
transferase<250 U/L, creatinine<2.0mg/dL, and no clinically evident cardiac
dysfunction). The protocol was approved by the Asan Medical Center Insti-
tutional Review Board and Korean Food and Drug Administration and is
registered at ClinicalTrial.gov as #NCT00823524. All patients and donors
provided written informed consent. Patient and donor HLA-A, -B, -C, and
-DRB1 typing and donor KIR genotyping were performed by PCR-based
methods. The methodology for haploidentical HCT used in the study has
been described previously [4,26]. Brieﬂy, the conditioning regimen included
busulfan 3.2 mg/kg/day intravenously (i.v.) on days 7 and 6 of HCT (day
0 being the ﬁrst day of donor cell infusion), ﬂudarabine 30 mg/m2/day i.v. on
days 7 to 2, and thymoglobulin (Genzyme Transplant, Cambridge, MA)
3 mg/kg/day i.v. on days 4 to 1 (initial 6 patients) or on days 3 to 1
(subsequent 35 patients; ATG dose reduced because of newly imposed re-
striction from the Korean national health insurance). Granulocyte colony-
stimulating factor (G-CSF) 450 mg was infused i.v. daily starting on day 5
until absolute neutrophil counts (ANC) recovered to 3000/mL. Eleven patients
with refractory acute leukemia experienced rapid increases in white blood
cell count and received ara-C 200 to 500 mg/m2/day intravenously for 2 to
5 days within the 2 weeks before the conditioning therapy. For GVHD pro-
phylaxis, all patients received cyclosporine. Additionally, 28 patients received
methotrexate 15mg/m2 i.v. 1 day and 10mg/m2 3, 6, and 11 days after the last
donor cell infusion. Thirteenpatients did not receivemethotrexate because of
liver function abnormalities (n ¼ 4) or sepsis (n ¼ 1), or per the physician’s
decision (n ¼ 8). Beginning with the 24th patients in the study, azithromycin
125 to 250 mg was given orally daily from 3 weeks after HCT, which was
continued for over a year [27].
Beginning on day 3, each hematopoietic cell donor was given G-CSF
10 mg/kg subcutaneously daily for 5 to 6 days. Starting on the fourth day of
G-CSF administration (day 0 of HCT), donor mononuclear cells were har-
vested daily by large-volume leukapheresis (CS3000, Baxter, Deerﬁeld, IL)
for 3 (n¼ 32) or 4 days (n¼ 9). The cells collected during the ﬁrst 2 to 3 days
were administered to patients through central venous catheters on the same
day. The cells collected on the last day were transported to a Korean Food
and Drug Administrationeinspected laboratory, located in the hospital, for
NK cell generation (see below).Per the protocol design, at least 3 patient cohorts each were planned to
receive .2  108, .5  108, 1.0  108, and > 1.0  108 donor NK cells/kg body
weight, twice at 2 (DNKI-1) and 3 weeks (DNKI-2) after HCT. NK cell dose
escalation was allowed when none of the patients in each dose level
experienced grade 3 acute toxicity or GVHD. In the initial phase of the study,
all 6 patients who received DNKI at .2  108 and .5  108 cells/kg tolerated
the procedure well without acute toxicity and none experienced grade 3
acute GVHD. Thereafter, of the 8 patients who received 1.0  108 cells/kg, 2
experienced grade 3 acute GVHD. For patients who enrolled subsequently,
donor NK cell doses were based on the quantity of the cells generated; ie, for
DNKI-1, 1 to 2  108 donor NK cells/kg or about one half of cell culture
products were administered. For DNKI-2, the remaining cell culture prod-
ucts were administered. Donor NK cells were infused over an hour through a
central venous catheter, with pheniramine 45.5 mg given by brief i.v. infu-
sion 30 minutes prior.
Patient Evaluation
Criteria for neutrophil and platelet engraftment [4], and acute and
chronic GVHD [28,29] have been described. Bone marrow was biopsied on
the day before conditioning therapy and again 4 to 5 weeks after HCT.
Complete remission (CR) of acute leukemia or MDS was deﬁned as the re-
covery of a peripheral blood ANC to >1,000/mL and evidence of donor cell
regeneration in a bone marrow aspirate with  5% blasts. In patients with
documented CR, leukemia progression was deﬁned as >5% leukemic blasts
in a bone marrow sample. In patients with persistent leukemia after HCT,
the day of progression was deﬁned as the day on which leukemia blasts
reappeared in the peripheral blood, with bone marrow examination
showing >5% persistent blasts. In a patient with lymphoma, disease pro-
gression was deﬁned as >20% increment of lung lesion diameters. He-
matopoietic chimerism was assessed 30, 90, and 180 days after HCT by a
PCR-based procedure utilizing short tandem DNA repeats.
Statistical Analyses
Any untoward reaction associated with DNKI was assessed. Post-
transplantation events, such as donor cell engraftment, GVHD, and TRM,
were recorded. In patients with refractory hematologic malignancy, the
antileukemia/lymphoma effect of the treatment was evaluated by CR and
disease progression. Times to engraftment, GVHD, TRM, and disease pro-
gressionwere measured fromHCT, estimated using the cumulative incidence
function [30], and compared using Gray methods [31]. Death and disease
progression were considered as competing risks in analyses of engraftment
and GVHD. TRM and progression were considered to be mutually competing
risks. Achievement of CR was compared using chi-square test. Overall sur-
vival (OS) was measured from HCT to death or last follow-up. Event-free
survival (EFS) was measured from HCT to disease progression, death without
disease, or last follow-up. OS and EFSwere estimated using the Kaplan-Meier
method and compared using the log-rank test.
To serve as a reference cohort, we identiﬁed patients with refractory
acute leukemia from our previously published cohort of 86 patients who
underwent haploidentical HCT in our hospital [4]. Of 34 patients with re-
fractory acute leukemia at the time of HCT in that study, 2 patients were
enrolled in the current study and received high-dose DNKI after hap-
loidentical HCT (Unique patient numbers [UPNs] 726 and 749)
(Supplementary Table 1). Further, another patient died early with sepsis on
the day of HCT. Thus, the remaining 31 patients (ages 16 to 68 years)
constituted the historical reference cohort. These patients underwent hap-
loidentical HCT between June 2004 and December 2009, received either no
post-transplantation DNKI (n ¼ 24) or low-dose DNKI (.3 to 24.5  106/kg)
6 weeks after HCT (n ¼ 7) [19], and survived at least .5 months after HCT.
Together, the patients in the study and historical cohorts represent consec-
utive series of patients who underwent haploidentical HCT in a single
institution using the same conditioning regimen and supportive care. The
demographics of historical patients and their donors are described in Table 1.
To identify variables with prognostic signiﬁcance in the combined
cohort of study and historical patients, age (50 versus >50 years), gender,
diagnosis (acute myelogenous leukemia [AML] versus acute lymphoblastic
leukemia [ALL]/lymphoma), previous allogeneic HCT, antithymocyte glob-
ulin doses (3 versus 4), donor relation, donor age (30 versus >30 years),
donor gender, donor-patient HLA-mismatch (3/8 versus 4/8 alleles),
donor-patient NK cell alloreactivity [13], graft mononuclear cell dose (7
versus >7  108/kg), graft CD34þ cell dose (5 versus >5  106/kg), graft
CD3þ cell dose (5 versus >5  108/kg), and graft NK cell dose (.9
versus >.9  108/kg) were analyzed by univariate analysis. Variables with a
P < .05 as determined by univariate analysis were entered into multivariate
analysis by the Fine and Gray model (engraftment, acute and chronic GVHD,
TRM, and disease progression) [32] or the Cox proportional hazards model
(EFS and OS ﬁgures). Additionally, within the study cohort, donor KIR
genotype (2DS1-positive versus negative; 3DS1-positive versus negative,
Figure 1. Treatment paradigm and clinical outcomes. (A) Shows outlines of the treatment paradigm of HLA-haploidentical hematopoietic cell transplantation (HCT)
and subsequent donor natural killer (NK) cell infusion (NDKI). Patients received conditioning therapy for HCT with busulfan, ﬂudarabine, and antithymocyte globulin
between days -7 and -1. Hematopoietic cell donors received granulocyte colonyestimulating factor starting on day -3 and underwent large-volume leukapheresis for
3 to 4 days (depending on the number of CD34þ cells collected during the ﬁrst 2 days), beginning on day 0. The goal was to transplant > 5  106 CD34þ cells/kg.
Mononuclear cells collected on the ﬁrst 2 to 3 days were transplanted into the patients on the same day. Cells collected on the last day were transported to the
laboratory, where they were depleted of CD3þ cells, then differentiated into NK cells ex vivo. Donor NK cells thus generated were infused into patients twice 2 and
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[90% versus >90%], NKG2D [ 90% versus >90%], KIR2DL1 [15%
versus >15%], NKp46 [80% versus >80%]), and DNKI-1 and -2 doses (.9
versus >.9  108/kg) were analyzed for their prognostic signiﬁcance.Donor NK Cell Generation and Evaluation
CD3þ cells were depleted from the leukapheresis product by CliniMACS
(Miltenyi Biotec GmbH, Bergisch Gladhach, Germany) or RosetteSep
(Stemcell Technologies Inc., Vancouver, Canada) systems. CD3-depleted cells
were then cultured in a-MEM media (Welgene, Daegu, Korea) supple-
mented with human interleukin (IL)-15 (10 ng/mL, PeproTech, Rocky Hill,
NJ), human IL-21 (10 ng/mL, PeproTech), and hydrocortisone (106 M,
Stemcell Technologies) in a humidiﬁed 5% CO2 atmosphere at 37C. One half
the mediawas replaced with fresh complete media twice weekly. After 13 to
20 days of cultivation, cells were harvested, suspended in 100 mL human
albumin solution (5%), and infused into patients after appropriate quality
assurance procedures.
NK cell products were immunophenotyped by ﬂow cytometry after
ﬂuorescence labeling. Cell viability was determined by labeling differenti-
ated cells with propidium iodide and analyzing by ﬂow cytometry. The
ability of donor NK cells to kill target cells was measured against the pa-
tients’ pretransplantation bone marrow cells or K652 cells using 51Cr or
calcein-release assay. Perforin and granzyme gene expression in donor NK
cells was detected by reverse transcriptase (RT)-PCR. Donor NK cell cytokine
secretion was determined by measuring interferon (IFN)-g and tumor ne-
crosis factor (TNF)-a in culture supernatant by enzyme-linked immuno-
sorbent assay.RESULTS
Patient and Donor Demographics
The patient and donor demographics are summarized
in Table 1. Individual patient-donor data are listed in
Supplementary Table 1. The median patient agewas 47 years.
Thirty-two patients had AML, 7 had ALL, 1 MDS, and 1 had
diffuse large B cell lymphoma. At the time of HCT, 37 of the
40 patients with hematologic malignancies had active, re-
fractory disease; 35 in the bone marrow (median blasts 55%;
range, 8% to 98%), and 1 each in the leptomeninges (UPN 726)
and in the lung (UPN 905).
The median donor age was 32 years (range, 7 to 62 years).
There were a mean of 3.38 donor-patient mismatches of the
8 HLA-A, -B, -C, and -DRB1 alleles in the graft-versus-host
direction and a mean of 3.68 mismatches of 8 alleles in the
rejection direction. Seven of 40 evaluated donor-recipient
pairs (18%) exhibited NK cell alloreactivity when classiﬁed
according to KIR ligand incompatibility [13]. The median
number of CD34þ cells transplanted was 7.2  106/kg.Donor-derived NK Cells
Four patients did not receive DNKI-2 because of sepsis
(n ¼ 2) (Supplementary Table 1), respiratory failure (n ¼ 1),
or NK cell expansion failure (n ¼ 1). Characteristics of
the donor NK cells are summarized in Table 2; individual
donor cell data are listed in Supplementary Table 2 and
Supplementary Table 3. Before CD3þ cell depletion, the leu-
kapheresis products contained a median 24.3  109 mono-
nuclear cells with median CD56þCD122þ and CD3þ rates of
8% and 64%, respectively. After CD3þ cell depletion, the
medianmononuclear cell count decreased to 15.4109, with
median CD56þCD122þ and CD3þ rates of 29% and .8%,
respectively. During 2 to 3 weeks of cell culture, there was a3 weeks after HCT. Cumulative incidences of neutrophil and platelet engraftment (B),
treatment-related mortality (D) assessed in the 41 study patients and 31 historical pa
was assessed in 37 patients who had active, refractory acute leukemia (n ¼ 36) or lym
historical patients. Cumulative incidences of disease progression (E) and Kaplan-Me
diagnosis.median 3.7-fold (range, .8 to 70.0) increase in CD56þCD122þ
cell counts.
Median cell viability in the ﬁnal culture product ranged
from 71% to 85%. Immunophenotype analyses showed me-
dian CD56þCD122þ rates of >90% and median CD3þCD56þ
rates of <3%. Additionally, they showed other cell markers
such as CD19þ, CD15þ, and gd TCRþ rates of < 3%
(Supplementary Figure S1). One case (UPN 966) had high
CD3þCD56- rates; 16% for DNKI-1 and 7% for DNKI-2. The
other cases had median CD3þCD56- rates <.3%. All donor-
derived NK cells expressed inhibitory as well as activating
receptors in varying degrees. After 17 days of culture, NK cells
became mature NK cells (median CD56þCD16þ rates of 67%)
(Supplementary Figure S2). RT-PCR assay showed that all
ﬁnal donor NK cell products expressed the granzyme or
perforin gene. IFN-g or TNF-a were detected in all the ﬁnal
cell culture supernatants. 51Cr or calcein-release assays, us-
ing patients’ pretransplantation bone marrow cells (n ¼ 8;
with 46% to 95% blasts) or K562 cells as a target, demon-
strated that all donor NK cells possessed cytotoxic activity
(median cytotoxicity against bone marrow blasts, about
45% at effector to target ratio of 2:1) (Supplementary
Figure S3).
Engraftment, GVHD, and TRM
Individual outcomes of haploidentical HCT and DNKI
are listed in Supplementary Table 4. In all study patients,
DNKI was well tolerated without acute side effects. Thirty-
ﬁve recipients achieved initial donor cell engraftment with
ANC  500/mL at a median of 13 days (range, 8 to 43 days)
after HCT (cumulative incidence, 85%; 95% conﬁdence in-
terval [CI], 75% to 97%) (Figure 1B). One patient (UPN
1136) experienced primary engraftment failure. The
remaining 5 patients experienced early leukemia pro-
gression (n ¼ 3) or TRM (n ¼ 2). Thirty-one patients
achieved platelet counts  20,000/mL at a median of
16 days (range, 8 to 77 days; cumulative incidence, 78%).
All 33 patients without leukemia progression, TRM, or
engraftment failure achieved donor peripheral blood
mononuclear cell chimerism >90% by 30 days after HCT.
One patient (UPN 1093) experienced secondary graft fail-
ure 2 months after HCT.
Nine patients in the study experienced acute GVHD (cu-
mulative incidence, 22%; 95% CI, 12% to 39%) at a median of
.8 months after HCT (range, .5 to 1.7 months) (Figure 1C). Of
these, 7 patients had grade 2 to 4 acute GVHD (cumulative
incidence, 17%) and 5 had grade 3 or 4 acute GVHD (cumu-
lative incidence, 12%). Chronic GVHD occurred in 10 patients
(cumulative incidence, 24%; 95% CI, 14% to 42%) at a median
of 3.3 months after HCT (range, 2.6 to 4.6 months)
(Figure 1D) with 6 patients experiencing severe chronic
GVHD (cumulative incidence, 15%). In total, 11 patients in the
study died without progression of underlying malignancies
or MDS, resulting in a cumulative TRM incidence of 27% (95%
CI, 16% to 45%) (Figure 1D).
In the historical cohort of 31 patients, the cumulative
incidences of neutrophil engraftment, platelet engraftment,
grade 2 to 4 acute GVHD, moderate to severe chronic GVHD,acute graft-versus-host disease (C), chronic graft-versus-host disease (D), and
tients are depicted. The antileukemia/lymphoma effect of the study treatment
phoma (n ¼ 1) at the time of hematopoietic cell transplantation along with 31
ier plots of event-free (F) and overall (G) survival are shown according to the
Table 2
Characteristics of Donor Natural Killer Cells
Characteristics DNKI-1 (n ¼ 41) DNKI-2 (n ¼ 37)
Cell dose
Level 1 (3 patients) .2  108/kg .2  108/kg
Level 2 (3 patients) .5  108/kg: .5  108/kg
Level 3 (8 patients) 1.0  108/kg 1.0  108/kg
Level 4 (27 patients),
median (range)
1.0 (.3-2.0)  108/kg 2.0 (.2-5.0)  108/kg
Cell viability, median
(range), %
85 (58-98) 71 (43-95)
Immunophenotype,
median (range), %
CD56þCD122þ 91 (49-99) 95 (76-99)
CD3þCD56þ 1.1 (.1-8.6) 2.6 (.5-6.8)
CD3þCD56e* .2 (0-2.1) .2 (0-1.2)
Receptor expression,
median (range), %
CD94 93 (38-99) 95 (63-99)
NKG2D 86 (3-99) 93 (3-100)
KIR2DL1 17 (4-95) 14 (1-90)
KIR2DL2/3 19 (6-67) 20 (1-96)
KIR3DL1 11 (4-24) 11 (3-38)
NKp46 82 (10-98) 89 (8-99)
NKp44 22 (1-99) 46 (11-100)
NKp30 93 (31-100) 97 (7-100)
Granzyme gene
expression, no. (%)
36 (88) 37 (100)
Perforin gene expression,
no. (%)




INFeg 87 (0-786) 176 (0-1139)




ET ratio, 10:1 75 (36-93) 68 (35-97)
ET ratio, 5:1 68 (21-88) 63 (25-94)
ET ratio, 2.5:1 61 (12-86) 58 (13-88)
Cell cytotoxicity against
bone marrow blasts
(n ¼ 8) (%), median
(range)
ET ratio, 2:1 45 (26-77) 45 (23-76)
DNKI indicates donor natural killer cell infusion; IFN- g, interferon-g; TNF-a,
tumor necrosis factor-a; ET, effector to target ratio.
* One case (UPN 966) with a high percentage of CD3þCD56-, 16%, and 7%
for the DNKI-1 and -2, respectively, was excluded from the analysis.
Table 1





Patient age, median (range), yr 47 (17-75) 41 (16-68)
Older than 60 yr, no. (%) 9 (22) 3 (10)
Patient gender
Male 23 (56) 15 (48)
Female 18 (44) 16 (52)
Underlying disease
AML, CR1 3 (7)
AML, refractory 29 (71) 22 (71)
ALL, refractory 7 (17) 9 (29)
MDS RARS, refractory 1 (2)
Diffuse large B cell lymphoma,
refractory
1 (2)
Previous allogeneic HCT 4 (10) 4 (13)
Previous autologous HCT 1 (2) 1 (3)
Bone marrow blast percentage in
patients with refractory acute
leukemia, median (range)
55 (8-98) 23 (0-89)
Antithymocyte globulin doses
in conditioning*
3 35 (85) 6 (19)
4 6 (15) 25 (81)
Donor age, median (range), yr 32 (7-62) 35 (3-68)
Donor gender
Male 25 (61) 19 (61)
Female 16 (39) 12 (39)
Donor relation to patient
Offspring 24 (59) 14 (45)
Sibling 9 (22) 9 (29)
Parents 8 (20) 8 (26)
No. of donor-patient HLA-A, -B, -C,
and -DRB1 allele mismatch, no.
GVH direction: 1, 2, 3, 4, unknown 1, 5, 12, 22, 1 0, 4, 4, 12, 11
Rejection direction: 1, 2, 3, 4,
unknown
0, 2, 9, 29, 1 1, 3, 6, 10, 11
Donor-patient NK cell alloreactivity
Yes 7 (17) 4 (13)
No 33 (80) 16 (52)
Unknown 1 (2) 11 (35)





CMV IgG serology of patient
Positive 40 (100) 31 (100)
Negative 0
Unknown 1
CMV IgG serology of donor
Positive 41 (100) 31 (100)
Negative 0
Number of transplanted cells,
median (range)
Mononuclear cells,  108/kg 9.0 (4.0-13.7) 8.6 (1.8-15.8)
CD34þ cells,  106/kg 7.2 (.8-16.5) 7.9 (.2-28.4)
CD3þ cells,  108/kg 6.4 (2.5-10.3) 5.2 (.5-10.0)
CD56þCD16þ cells,  108/kg .9 (.4-2.8) .9 (.2-2.0)
AML indicates acute myelogenous leukemia; CR1, ﬁrst complete remission;
ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; RARS,
refractory anemia with ring sideroblasts; HCT, hematopoietic cell trans-
plantation; HLA, human leukocyte antigen; NK, natural killer; KIR, killer
immunoglobulin-like receptor; CMV, cytomegalovirus.
Data presented are n (%) unless otherwise indicated.
* During the study period, the policy of Korean national health insurance
started to restrict total ATG dose that can be given during conditioning ther-
apy to  10 mg/kg, thus some of the patients receiving 3 doses of ATG only.
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Between the study and historical cohorts of patients, there
was no signiﬁcant difference in these HCT outcomes
(Figure 1B-D, Table 3).Complete Remission, Disease Progression, and Patient
Survival
The surviving patients in the study were followed for a
median of 31.5 months (range, 16.6 to 53.0 months). All
3 AML patients who were in their ﬁrst CR at HCT experi-
enced recurrent leukemia at 6, 34, and 49 months
(Supplementary Table 4). One patient with MDS was well in
CR at 53 months.
Among the 37 patients who had refractory acute leuke-
mia (n ¼ 36) or lymphoma (n ¼ 1) at the time of HCT, 25
(68%) achieved CR after HCTand DNKI; CR rates were 72% (21
of 29) for AML patients and 50% (4 of 8) for ALL/lymphoma
patients. In total,17 patients in the study experienced disease
progression (cumulative incidence, 46%); the cumulative
incidence of disease progression in AML patients was 38%
and that of ALL/lymphoma patients was 75% (Figure 1E).
Cumulative EFS and OS rates for refractory AML were 31%
and 35%, respectively. The EFS and OS rates for refractory
ALL/lymphoma were both 0% (Figure 1F,G).
In the historical cohort of 31 patients, CR rate, cumulative
incidence of disease progression, cumulative EFS rate, and
Table 3
Univariate and Multivariate Analyses in the Combined Cohort of Study and Historical Patients
Variables Categories Grades 2 to 4 Acute







Univariate analyses (no. of patients with an event or death)
Patient cohort Study versus historical NS P ¼ .038 (17 of 37
versus 23 of 31)
NS NS
Diagnosis Refr. AML versus
ref. ALL/lymphoma
NS P ¼ .011 (27 of 51
versus 13 of 17)
P ¼ .008 (40 of 51
versus 17 of 17)
P ¼ .0360 (39 of 51
versus 17 of 17)
Donor sex Male versus female P ¼ .0271 (4 of 44
versus 8 of 28)
NS NS NS
Donor relation Offspring versus
sibling/parents
P ¼ .0314 (3 of 38
versus 9 of 34)
NS NS NS
Multivariate analysis (hazard ratio [95% CI])
Patient cohort Study versus historical NS P ¼ .042 (.527 [.285-.976]) NS NS
Diagnosis Refr. AML versus
refr. ALL/lymphoma
NS P ¼ .045 (.486 [.240-.983]) P ¼ .010 (2.154 [1.201-3.865]) P ¼ .039 (1.868 [1.032-3.381])
GVHD indicates graft-versus-host disease; ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; refr., refractory; CI, conﬁdence interval; NS,
not signiﬁcant.
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Between the study and historical cohorts, the study cohort of
patients experienced signiﬁcantly less disease progression
(46% versus 74%, P ¼ .038).
Univariate and Multivariate Analyses
When univariate analyses were performed in the com-
bined cohort of study and historical patients, none of the
evaluated variables showed signiﬁcant correlation with
neutrophil and platelet engraftment, chronic GVHD, TRM, or
CR achievement. Donor sex and donor relation showed sig-
niﬁcant correlation with grade 2 to 4 acute GVHD (Table 3).
As mentioned above, patient cohort (study versus historical)
showed signiﬁcant correlation with disease progression.
Diagnosis (AML versus ALL/lymphoma) showed signiﬁcant
correlation with disease progression, EFS, and OS. Multivar-
iate analysis showed that patient cohort (study versus his-
torical) was an independent predictor for less disease
progression (hazard ratio, .527). Additionally, the diagnosis
(AML versus ALL/lymphoma) was an independent predictor
for less disease progression (hazard ratio, .486) and longer
EFS (hazard ratio, 2.154) and OS (hazard ratio, 1.868).
When analyzed within the study cohort, donor KIR ge-
notype, donor NK cell receptor expression, and DNKI dose
did not show signiﬁcant correlation with outcomes; how-
ever, because of the small number of patients in our study,
these need further investigation in future studies.
Infections and Lymphocyte Reconstitution after
HLA-haploidentical HCT and DNKI
Within 100 days after HCT, 29 of 32 evaluated study
patients (91%) had at least 1 positive assay for cytomegalo-
virus pp65 antigenemia; of these, 23 patients required pre-
emptive treatment with ganciclovir. Twenty-three of 32
evaluated study patients (72%) showed Epstein-Barr virus
DNA in blood by quantitative PCR; of these, 3 patients were
treated with rituximab (2 for febrile viral syndrome and 1 for
high titer). Other infections observed in the study were
cutaneous varicella zoster infection (n ¼ 2) and Pneumocystis
jiroveci pneumonia (n ¼ 2).
Post-transplantation measurement of lymphocyte subset
counts in 9 study patients showed that there were no obvious
changes in the peripheral blood lymphocyte subset counts,
including NK cells immediately after DNKI-1 and -2, although
more patients who receivedDNKI had NK cells with activating
receptors detected in the peripheral blood (Figure 2I). Theoverall immune reconstitution pattern after haploidentical
HCT and DNKI was that the NK cell count recovered earliest,
exceeding the pretransplantation count at 1 month, followed
by the CD8þ lymphocyte count, which exceeded the pre-
transplantation level at 2 months. There was a tendency for
higher post-transplantation T cell subset counts in patients
who received DNKI; CD4þ and CD4þ/CD25þ cell counts were
both signiﬁcantly higher (Figure 2B,D).
DISCUSSION
To our knowledge, ours is the ﬁrst study investigating the
clinical effect of donor NK cells given in a high dose after
HLA-haploidentical HCT. The median cell dose given in the
study was 2.0  108/kg, approximately 10 to 20 times higher
than those reported previously [16-19]. Of 27 patients who
received the total amount of NK cells generated, 26 patients
(96%) received  .9  108 cells/kg. In terms of the quality of
products, the median viability and CD56þ purity of NK cells
were around 80% and 93%, respectively. Excluding 1 case
with high expression, median CD3þCD56 rate was .2%.
Furthermore, these cells displayed characteristic NK cell
features, ie, granzyme and perforin gene expression, known
NK cell receptor expression, cytokine production, and in vitro
cell cytotoxicity.
When given 2 and 3 weeks after HCT, all our patients
tolerated DNKI well without acute toxicity, which corrobo-
rated other studies reporting general lack of toxicity as-
sociated with DNKI [16-24]. Furthermore, the cumulative
incidences of major HCT outcomes, such as engraftment,
acute and chronic GVHD, and TRM were similar to those of
historical patients who underwent haploidentical HCT at our
institution with the same conditioning regimen and sup-
portive care (but without high-dose DNKI), as well as to
those of other studies describing haploidentical HCT after
reduced-intensity conditioning [1-5].
Several ﬁndings in our study suggested that DNKI given
after haploidentical HCT may indeed provide an enhanced
antileukemia effect, especially against AML. When compared
with historical patients, there was a signiﬁcant reduction
in leukemia progression in the study patients (74% to 46%;
P ¼ .038). Post-transplantation high-dose DNKI was an in-
dependent factor predicting less leukemia progression
(hazard ratio, .527), along with the diagnosis (AML versus
ALL/lymphoma; hazard ratio, .486). Among 29 patients with
refractory AML in the study, 9 (31%) survived without leu-
kemia progression or TRM for 16.6 to 47.8 months.
Figure 2. Post-transplantation immune reconstitution. To measure the lymphocyte subsets after hematopoietic cell transplantation (HCT), peripheral blood
mononuclear cells were collected from the study and control patients on day -8 (before the conditioning therapy), day 13 (1 day before donor natural killer (NK)
infusion 2 weeks after HCT [DNKI-1]), day 15 (1 day after DNKI-1), day 17, day 20 (1 day before DNKI-2), day 24, day 28, and at 2, 3, 6, and 12 months after HCT.
Lymphocyte subsets were then measured by ﬂow cytometry after ﬂuorescence labeling with antihuman CD3, CD4, CD8, CD25, CD45RA, CD45RO, CD19, CD56, NKG2D,
CD122, CD69, NKp30, NKp44, NKp46, and KIR3DL1 antibodies. Patients with acute leukemia in the ﬁrst complete remission who underwent HLA-haploidentical HCT
without DNKI between November 2010 and February 2012, were evaluated as a control group. Median data from 9 study patients (black bars) and 8 control patients
(ages 20 to 62 years; 5 with AML and 3 with ALL; gray bars), who survived at least 6 months after HCT without leukemia progression are shown here. In both groups
of patients, CD8þ cells (A) and NK cells (G) showed early recovery achieving pretransplantation level at 2 months and 1 month, respectively. Patients who received
DNKI tended to show higher post-transplantation T cell subset counts with differences in the CD4þ cell count (B) and the CD4þ/CD25þ cell count (D) showing
statistical signiﬁcance at 3 months (median 67/mL versus 21/mL, P ¼ .043 and 9/mL versus 2/mL, P ¼ .001, respectively). Although the overall pattern of NK cell recovery
was similar between the 2 groups of patients, more patients who received DNKI showed NK cells with activating receptors early after DNKI. For example, 5 of 9 versus
none (P ¼ .024) had detectable CD56þ/NKp30þ cells on day 15 after HCT (I). The arrow indicates P < .05 as determined using the Mann-Whitney test. Error bars
represent maximum.
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resistant AML and received reduced-intensity conditioning
for HCT, it is likely that haploidentical HCT and subsequent
DNKI afforded a strong graft-versus-leukemia effect, over-
coming chemotherapy resistance in AML cells.
Human NK cells generated ex vivo were shown to have
high expression of activating receptors and killed target cells
immediately without prior exposure to human interleukin-2
[19]. In nude mice, cultured human NK cells survived for
2 weeks [19]. Infusion of haploidentical donor NK cells after
lymphodepletion with cyclophosphamide and ﬂudarabine
resulted in endogenous IL-15 surge and expansion of donor
NK cells up to 4 weeks [21]. In our study, NK cells were
derived from the same donor as used for HCT and, therefore,we were not able to evaluate their fate in vivo. However, it is
unlikely that they would be rejected by the patient immedi-
ately [13,15,34] and, considering the aforementioned animal
and clinical data, they might have persisted for several weeks.
Donor NK cells given to patients in our study showed in vitro
cytotoxicity against K562 cells and patients’ bone marrow
leukemia blasts. When we monitored our patients receiving
donor NK cells with frequent peripheral lymphocyte immu-
nophenotyping, there was no gross increase in NK cell count
immediately after DNKI. However, more patients receiving
DNKI showed detectable NK cells with activating receptors
in the peripheral blood (Figure 2I). Taken together, these
ﬁndings suggested that 1 of the main antileukemia mecha-
nisms of DNKI given in high doses in our study may be direct,
I. Choi et al. / Biol Blood Marrow Transplant 20 (2014) 696e704 703in vivo NK cell cytotoxicity against leukemia. Additionally,
other plausible mechanisms for the antileukemia effect may
be that NK cells given after haploidentical HCTact as initiators
or enhancers of a Tcellemediated antileukemia effect [35,36].
In our study, there was a tendency for earlier reconstitution of
lymphocyte subsets, especially CD4þ and CD4þ/CD25þ cells,
in patients receiving DNKI, which also suggests a role for NK
cells as enhancers of T cell reconstitution after HCT. Lastly,
part of the antileukemia effect observed in our study may be
due to coampliﬁed, donor T cells infused along with NK cells.
It is interesting to note that DNKI given in our study was
more effective in patients with AML than in patients with ALL.
Increased clinical efﬁcacy of NK cellealloreactivity in myeloid
over lymphoid leukemia has been described [13]. The under-
lying mechanisms of this phenomenon remain to be studied,
although a study described that myeloid leukemia, compared
with lymphoid leukemia, presents a downregulation of HLA-
class I molecules, as well as higher expression of activating
ligands, such as CD 112 and CD155 [37].
It should be noted that the main conclusions from our
study were drawn from a comparison with historical pa-
tients, which is heterogenous and small group. Furthermore,
leukemia progression in these historical patients was 74%,
which may be excessive, thus making that of current treat-
ment group appeared lower. Therefore, further studies of
larger cohorts of patients with deﬁned diagnoses and disease
status are necessary. Close patient monitoring of short- and
long-term adverse reactions associated with DNKI is
mandatory. Furthermore, considering ethnic variation of HLA
and NK cell receptor gene frequencies [38,39], the ﬁndings in
our study should be conﬁrmed in other patient populations.
Although our study did not show any prognostic signiﬁcance
of several aspects of NK cell biology, such as donor-patient NK
cell alloreactivity, donor KIR genotype, and the degree of
donor NK cell receptor expression, these variables should be
re-evaluated in larger cohorts of patients. Lastly, in future
DNKI trials, any effects of antithymocyte globulin, an immu-
nosuppressant known to have a prolonged half-life in the
blood [40,41] and prophylactic cyclosporine [42] have on
donor NK cells should be investigated.
Optimum methods of DNKI after HCT remain to be
deﬁned. In our study, 2 to 3 weeks’ time was required for
donor NK cell generation; however, with improved NK cell
generation or an extra session of donor cell collection in
advance, earlier administration of DNKI may be considered.
Likewise, any advantage or disadvantage of split DNKI versus
single DNKI is unknown.
In conclusion, our study showed that .3 to 6.0  108/kg,
clinical-grade NK cells can be generated from a 1-day leu-
kapheresis product from donors. When given 2 to 3 weeks
after HLA-haploidentical HCT, these donor-derived NK cells
were well tolerated by patients. Furthermore, they may
decrease leukemia progression, especially in patients with
AML. Therefore, in the management of patients with re-
fractory acute leukemia, haploidentical HCT and subsequent
DNKI remains to be 1 of the therapeutic strategies that need
further investigation.
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